Summary
Prostaglandins and other eicosanoids have been studied extensively in their physical, biochemical, biophysical and pharmacological aspects. However, studies on their role in tumor progression, especially metastases are relatively recent. Following a brief overview of the history of discovery and metabolism of eicosanoids and other fatty acids, we discuss the functions of these fatty acids (with emphasis on prostacyclin, thromboxane A2, 12-hydroxyeicosatetraenoic acid and 13-hydroxyoctadecadienoic acid) in cell transformation, tumor promotion and particularly in tumor cell metastasis. The relation between these monohydroxy fatty acids and tumor cell metastasis is discussed from three different perspectives, i.e., their effects on tumor cells, on platelets and on endothelial cells. The mechanism of these effects are then addressed at cell adhesion molecule, motility, protease, cell cytoskeleton, protein kinase and eicosanoid receptor levels. Finally, regulation of three key enzymes which generate eicosanoids (phospholipase, prostaglandin endoperoxide synthase and lipoxygenase) is explored.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
SamuelssonB, GoldyneM, GranstromE, HambergM, HammarstromS, MalmstenC: Prostaglandins and thromboxanes. Ann Rev Biochem 47: 997–1029, 1978
NeedlemanP, TurkJ, JakschikBA, MorrisonAR, LefkowithJB: Arachidonic acid metabolism. Ann Rev Biochem 55: 69–102, 1986
PiperPJ, SamhounMN: Leukotrienes. Brit Med Bull 43: 297–311, 1987
SpectorAA, GordonJA, MooreSA: Hydroxyeicosatetraenoic acids (HETEs). Prog Lipid Res 27: 271–323, 1988
PapatheofanisFJ, LandsWEM: Lipoxygenase mechanisms. In: LandsWEM (ed) Biochemistry of arachidonic acid metabolism. Martinus Nijhoff Publishing, Boston, 1985, pp 9–39
DixonRAF, JonesRE, DiehlRE, BennettCD, KargmanS, RouzerCA: Cloning of the cDNA for human 5-lipoxygenase. Proc Natl Acad Sci USA 85: 416–420, 1988
BalcarekJM, TheisenTW, CookMN, VarrichioA, HwangS, StrohsackerMW, CrookeST: Isolation and characterization of a cDNA clone encoding rat 5-lipoxygenase. J Biol Chem 263: 13937–13941, 1988
FunkCD, FurciL, FitzgeraldGA: Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc Natl Acad Sci USA 87: 5638–5642, 1990
YoshimotoT, SuzukiH, YamamotoS, TakaiT, YokoyamaC, TanabeT: Cloning and sequence analysis of the cDNA for arachidonate 12-lipoxygenase of porcine leukocytes. Proc Natl Acad Sci USA 87: 2142–2146, 1990
DeMarzoN, SloaneDL, DicharryS, HighlandE, SigalE: Cloning and expression of an airway epithelial 12-lipoxygenase. Am J Physiol 262: L198-L207, 1992
SigalE, CraikCS, HighlandE, GrunbergerD, CostelloLL, DixonRAF, NadelJA: Molecular cloning and primary structure of human 15-lipoxygenase. Biochem Biophys Res Commun 157: 457–464, 1988
O'PreyJ, ChesterJ, ThieleBJ, JanetzkiS, PrehnS, FlemingJ, HarrisonPR: Promoter structure and complete sequence of the gene encoding the rabbit erythroid cell-specific 15-lipoxygenase. Gene 84: 493–499, 1989
YokoyamaC, TanabeT: Cloning of human encoding prostaglandin endoperide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 165: 888–894, 1989
DeWittAL, El-HarithEA, KraemerSA, AndrewsMJ, YaoEF, ArmstrongRL, SmithWL: The aspirin and heme-binding site of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 265: 5192–5198, 1990
DeWittDL, SmithWL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85: 1412–1416, 1988
FunkCD, HoshikoS, MatsumotoT, RadmarkO, SamuelssonB: Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA 86: 2587–2591, 1989
KraemerSA, MeadeEA, DeWittDL: Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 293: 391–400, 1992
HammarstromS: Biosynthesis and biological actions of prostaglandins and thromboxanes. Arch Biochem Biophys 214: 431–445, 1982
HammarstromS: Prostaglandin production by normal and transformed 3T3 fibroblasts in cell culture. Eur J Biochem 74: 7–12, 1977
RitziEM, StylosWA: Prostaglandin production in cultures of Balb/3T3 and SV3T3 mouse fibroblasts. J Natl Cancer Inst 56: 529–533, 1976
BarkerK, AderemA, HanafusaH: Modulation of arachidonic acid metabolism by Rous sarcoma virus. J Virol 63: 2929–2935, 1989
AlonsoT, MorganRO, MarvizonJC, ZarblH, SantosE: Malignant transformation by ras and other oncogene produces common alterations in inositol phospholipid signaling pathways. Proc Natl Acad Sci USA 85: 4271–4275, 1988
HanJ, SadowskiH, YoungDA, MacaraIG: Persistent induction of cyclooxygenase in p60v-src transformed 3T3 fibroblasts. Proc Natl Acad Sci USA 87: 3373–3377, 1990
XieW, ChipmanJG, RobertsonDL, EriksonRL, SimmonsDL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692–2696, 1991
KarimSMM, RaoB: Prostaglandins and tumors. In: KarimSMM (ed) Prostaglandins: Physiological, pharmacological and pathological aspects. Univ Park Press, Baltimore, 1976, pp 303–325
Levine L: Arachidonic acid transformation and tumor production. In: Lein G, Weinmhouse S (eds) Advances in cancer research. Academic Press, 1981, 35: 49–79
Levine L: Tumor promoters and prostaglandin production. In: Nigam SK, McBrien DCH, Slater TF (eds) Eicosanoids, lipid peroxidation and cancer. Springer-Verlag, 1988, pp 11–21
Ullrich V, Hecker M, Nusing R, Rosenbach T: Thromboxane A2 and prostacyclin in tumorigenesis. In: Nigam SK, McBrien DCH, Slater TF (eds) Eicosanoids, lipid peroxidation and cancer. Springer-Verlag, 1988, pp 4–10
WuKK, HatzakisH, LoSS, SeongDC, SandujaSK, TaiHH: Stimulation ofde novo synthesis of prostaglandin G/H synthase in human endothelial cells by phorbol ester. J Biol Chem 263: 19043–19047, 1988
OhuchiK, LevineL: Stimulation of prostaglandin synthesis by tumor-promoting phorbol-12,13-diesters in canine kidney (MDCK) cells. J Biol Chem 253: 4783–4790, 1978
ZenserTV, ElingTE, DuniecZM, HuangYH, DavisBB: Mechanism of 12-O-tetradecanoylphorbol-13-acetate enhanced metabolism of arachidonic acid in dog urothelial cells. Cancer Res 50: 4650–4655, 1990
DuniecZM, NettesheimP, ElingTE: Stimulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by phorbol ester: mediation by protein kinase C. Mol Pharmacol 39: 164–170, 1990
ParkerJ, DanielLW, WaiteM: Evidence of protein kinase C involvement in phorbol diester-stimulated arachidonic acid release and prostaglandin synthesis. J Biol Chem 262: 5385–5393, 1987
HabenichtAJR, GoerigM, GrulichJ, RotheD, GronwaldR, LothU, SchettierG, KommerellB, RossR: Human platelet-derived growth factor stimulates prostaglandin synthesis by activation and by rapidde novo synthesis of cyclooxygenase. J Clin Invest 75: 1381–1387, 1985
LinAH, BienkowskiMJ, GormanRR: Regulation of prostaglandin H synthase mRNA levels and prostaglandin biosynthesis by platelet-derived growth factor. J Biol Chem 264: 17379–17383, 1989
YokotaK, KusakaM, OhshimaT, YamamotoS, KuriharaN, YoshinoT, KumegawaM: Stimulation of prostaglandin E2 synthesis in cloned osteoblastic cells of mouse (MC3T#-E1) by epidermal growth factor. J Biol Chem 261: 15410–15415, 1986
CaseyML, KorteK, MacDonaldPC: Epidermal growth factor stimulation of prostaglandin E2 biosynthesis in amnion cells, induction of prostaglandin H2 synthase. J Biol Chem 263: 7846–7854, 1988
TopleyN, FloegeJ, WesselK, HassR, RadekeHH, KaeverV, ReschK: Prostaglandin E2 production is synergistically increased in cultured human glomerular mesangial cells by combinations of IL-1 and tumor necrosis factor-α. J Immunol 143: 1989–1995, 1989
RazA, WycheA, SiegelN, NeedlemanP: Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 263: 3022–3028, 1988
MaierJAM, HlaT, MaciagT: Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 265: 10805–10808, 1990
KusakaM, OshimaT, YokotaK, YamamotoS, KumegawaM: Possible induction of fatty acid cyclooxygenase in mouse osteoblastic cells (MC3T3-E1) by cAMP. Biochim Biophys Acta 972: 339–346, 1988
HartIR, GoodeNT, WilsonRE: Molecular aspects of the metastatic cascade. Biochim Biophys Acta 989: 65–84, 1989
WeissL, OrrFW, HonnKV: Interactions of cancer cells with the microvasculature during metastasis. FASEB J 2: 12–21, 1988
Honn KV, Menter DG, Steinert BW, Taylor JD, Onoda JM, Sloane BF: Analysis of platelet, tumor cell and endothelial cell interactionsin vivo andin vitro. In: Garaci E, Paoletti R, Santoro MG (eds) Prostaglandins in cancer research. Springer-Verlag, 1987, pp 172–183
CrissmanJD, HatfieldJS, MenterDG, SloaneBF, HonnKV: Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res 48: 4065–4072, 1988
KawaguchiT, NakamuraK: Cancer Metastasis Rev 5: 77–94, 1986
MenterDG, HatfieldJS, HarkinsCJ, SloaneBF, TaylorJD, CrissmanJD, HonnKV: Tumor cell-platelet interactionsin vitro and their relationship toin vivo arrest of hematogenously circulating tumor cells. Clin Expl Metastasis 5: 65–78, 1987
MoncadaS, HiggsEA: Arachidonate metabolism in blood cells and the vessel wall. Clin Haemato 15: 273–292, 1986
BuchananMR, HaasTA: 13-hydroxyoctadecadienoic acid is the vessel wall chemorepellant factor, LOX. J Biol Chem 260: 16056–16059, 1985
PiperPJ, LettsLG, GaltonSA: Generation of a leukotriene-like substance from porcine vascular and other tissues. Prostaglandins 25: 591–599, 1983
HonnKV, CiconeB, SkoffA: Prostacyclin, a potent antimetastatic agent. Science 212: 1270–1272, 1982
SloaneBF, MakimS, DunnJR, LacosteR, TheodorouM, BattistaJ, AlexR, HonnKV: Lipoxygenase products as mediators of tumor cell lysosomal enzyme release: Inhibition by nafazatrom. Prostaglandins and cancer: First international conference, Alan R. Liss New York, NY10011, 1982, pp 789–792
HonnKV, BussWD, SloaneBF: Prostacyclin and thromboxanes: Implications for their role in tumor cell metastasis. Biochem Pharmacol 32: 1–11, 1983
MenterD, NeagosG, DunnJ, PalazzoR, TchenTT, TaylorJD, HonnKV: Tumor cell induced platelet aggregation: Inhibition by prostacyclin, thromboxane A2 and phosphodiesterase inhibitors. Prostaglandins and cancer: First international conference, Alan R. Liss New York, NY10011, 1982, pp 809–813
HonnKV, DunnJR: Nafazatrom inhibition of tumor cell lipoxygenase activity and cellular proliferation. FEBS Lett 139: 65–68, 1982
MarnettLJ, SiedlikPH, OchsRC, PagelsWR, DasM, HonnKV, WarnockRH, TainerBE, ElingTE: Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol 26: 328–335, 1984
Honn KV, Chen YQ: Prostacyclin, hydroxy fatty acids and tumor metastasis. In: Rubanyi GM, Vane JR (eds) Prostacyclin: New perspectives in basic research and novel therapeutic indications. Elsevier Science Publishers, Amsterdam, The Netherlands, in press
HonnKV, GrossiIM, TimarJ, ChopraH, TaylorJD: Platelets and cancer metastasis. In: OrrFW, BuchananM, WeissL (eds) CRC Press, Inc., Boca Raton, FL, 1991, pp 93–110
ChopraH, TimarJ, RongX, GrossiIM, HatfieldJS, FligielSEG, FinchCA, TaylorJD, HonnKV: Is there a role for the tumor cell integrin αIIbβ3 and cytoskeleton in tumor cell-platelet interaction. Clin Expl Metastasis 10: 125–138, 1992
Steinert BW, Tang DG, Jones CL, Grossi IM, Umbarger LA, Honn KV: Studies on the role of platelet eicosanoid metabolism and integrin αIIbβ3 in tumor cell induced platelet aggregation, submitted
Honn KV, Nelson KK, Renaud C, Bazaz R, Diglio CA, Timar J.: Fatty acid modulation of tumor cell adhesion to microvessel endothelium and experimental metastasis. Prostaglandins (in press)
GrossiIM, FitzgeraldLA, UmbargerLA, NelsonKK, DioglioCA, TaylorJD, HonnKV: Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid. Cancer Res 49: 1029–1037, 1989
HonnKV, GrossiIM, DiglioCA, WojtukiewiczM, TaylorJD: Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE-induced endothelial cell retraction. FASEB J 3: 2285–2293, 1989
Timar J, Chen YQ, Liu B, Bazaz R, Taylor JD, Honn KV: The lipoxygenase metabolite 12(S)-HETE promotes αIIbβ3 integrin mediated tumor cell spreading on fibronectin, Int J Cancer, in press
Tang D, Diglio CA, Honn KV: 12(S)-HETE-induced microvascular endothelial cell retraction is mediated by cytoskeletal rearrangement dependent on PKC activation. In: Nigam S, Honn KV, Marnett LJ, Walden T (eds) Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Kluwer Academic Publishers, 1992, pp 219–229
HonnKV, SteinertBW, MoinK, OnodaJM, TaylorJD, SloaneBF: The role of platelet cyclooxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation. Biochem Biophys Res Commun 29: 384–389, 1987
Grossi IM, Diglio CA, Honn KV: Control of tumor cell induced endothelial cell retraction by lipoxygenase metabolites, prostacyclin and prostacyclin analogues. In: Honn KV, Marnett LJ, Nigam S, Walden T (eds) Eicosanoids and other bioactive lipids in cancer and radiation injury. Kluwer Academic Publishers, 1991, pp 409–414
Marnett LJ, Leithauser MT, Richards KM, Blair I, Honn KV, Yamamoto S, Yoshimoto T: Arachidonic acid metabolism of cytosolic fractions of Lewis lung carcinoma cells. In: Samuelson B, Paoletti R, Ramwell P (eds) Adv Prostacyclin Thromboxane Leukotriene Res. Raven Press, 1991, 21: 895–900
Buchanan MR, Bertomeu MC, Bastida E, Orr FW, Gallo S: Eicosanoid metabolism and tumor cell endothelial cell adhesion. In: Honn KV, Marnett LJ, Nigam S, Walden T (eds) Eicosanoids and other bioactive lipids in cancer and radiation injury. Kluwer Academic Publishers, 1991, pp 347–350
Buchanan MR, Bertomeu MC, Gallo S, Orr FW: Fatty acid regulation of endothelial cell adhesion molecules and tumor cell adhesion: Implications in metastasis. In: Nigam S, Honn KV, Marnett LJ, Walden T (eds) Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Kluwer Academic Publishers, 1992, pp 619–622
Honn KV, Tang DG, Chen YQ: Platelets and cancer metastasis: More than an epiphenomenon. Sem Throm Hemost 18: 390–413
Fitzgerald LA, Phillips DR: Platelet membrane glycoproteins. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice.2nd ed, JB Lippincott, 1988, pp 572–593
PhillipsDR, CharoIF, ScarboroughRM: GpIIb-IIIIa: the responsive integrin. Cell 65: 359–362, 1991
GrossiIM, HatfieldJS, FitzgeraldLA, NewcombeM, TaylorJD, HonnKV: Role of tumor cell glycoproteins immunologically related to glycoproteins Ib and IIb/IIIa in tumor cell-platelet and tumor cell-matrix interactions. FASEB J 2: 2385–2395, 1988
ChangYS, ChengYQ, FitzgeraldLA, HonnKV: Analysis of integrin mRNA in human and rodent tumor cells. Biochem Biophys Res Commun 176: 108–113, 1991
Chen YQ, Gao X, Timar J, Tang D, Grossi IM, Chelladurai M, Kunicki TJ, Fligiel SEG, Taylor JD, Honn KV: Identification on the αIIbβ3 integrin in murine tumor cells. J Biol Chem, in press
Chen YQ, Gao X, Honn KV: Wide distribution of αIIb integrin among tumor cells: its potential importance. Submitted
ChopraH, TimarJ, ChenYQ, RongX, GrossiIM, FitzgeraldLA, TaylorJD, HonnKV: The lipoxygenase metabolite 12(S)-HETE induces cytoskeleton-dependent increase in surface expression of integrin αIIbβ3 on melanoma cells. Int J Cancer 49: 774–786, 1991
HonnKV, ChenYQ, TimarJ, OnodaJM, HatfieldJS, FligielSEG, SteinertBW, DiglioCA, GrossiIM, NelsonKK, TaylorJD: αIIbβ3 integrin expression and function in subpopulations of murine tumors. Exp Cell Res 201: 23–32, 1992
ChangYS, ChenYQ, TimarJ, NelsonKK, GrossiIM, FitzgeraldLA, DiglioCA, HonnKV: Increased expression of αIIbβ3 integrin in lung-colonizing subpopulations of murine melanoma cells. Int J Cancer 51: 445–451, 1992
Grossi IM, Honn KV: PG12 and its analogs inhibit 12-HETE induced expression of the αIIbβ3 integrin and adhesion in W256 carcinosarcoma cells. Submitted
Liu B, Renaud C, Nelson KK, Chen YQ, Bazaz R, Kowynia J, Timar J, Diglio CA, Honn KV: Protein kinase C inhibitor calphostin C reduces B16 amelanotic melanoma cell adhesion to endothelium and lung colonization. Int J Cancer 52: 147–152
Tang DG, Chen YQ, Renaud C, Diglio CA, Honn KV: PKC-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor. Submitted
Raz A, Silletti S, Timar J, Honn KV: Effect of 12-HETE on the expression of autocrine motility factor receptor and motility in melanoma cells. In: Nigam S, Honn KV, Marnett LJ, Walden T (eds) Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Kluwer Academic Publishers, 1992, pp 645–649
Sloane BF, Rozhin J, Gomez AP, Grossi IM, Honn KV: Effects of 12-hydroxyeicosatetraenoic acid on release of cathepsin B and cysteine proteinase inhibitors from malignant melanoma cells. In: Honn KV, Marnett LJ, Nigam S, Walden T (eds) Eicosanoids and other bioactive lipids in cancer and radiation injury. Kluwer Academic Publishers, 1991, pp 373–377
Taylor JD, Timar J, Tang D, Bazaz R, Chopra H, Kimler V, Honn KV: 12(S)-HETE induces cytoskeleton phosphorylations and rearrangement in melanoma cells. In: Nigam S, Honn KV, Marnett LJ, Walden T (eds) Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Kluwer Academic Publishers, 1992, pp 635–638
Liu B, Hannun YA, Khan WA, Renaud C, Wetsel WC, Honn KV: Alteration of membrane association of protein kinase Cα in B16 amelanotic melanoma cells by arachidonate and linoleate derived monohydroxy fatty acids. Submitted
Tang DG, Timar J, Grossi IM, Renaud C, Kimler VA, Diglio CA, Taylor JD, Honn KV: The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C dependent cytoskeletal rearrangement and retraction of microvascular endothelial cells. Submitted
Liu B, Marnett LJ, Blair I, Nelson KK, Renaud C, Diglio CA, Honn KV: Correlation of 12(S)-HETE and 13(S)-HODE biosynthesis to the metastatic potential of tumor cells. Submitted
SmithWL: The eicosanoids and their biochemical mechanisms of action. Biochem J 259: 315–324, 1989
SamuelssonB, GranstromE, GreenK, HambergM, HammarstromS: Prostaglandins. Ann Rev Biochem 44: 669–695, 1975
NicosiaS, PatronoC: Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention. FASEB J 3: 1941–1948, 1989
Gardiner PJ: Classification of prostanoid receptors. In: Samuelsson B, Dahlen S, Fritsch J, Hedqvist P (eds) Advances in prostaglandin, thromboxane and leukotriene research. Raven Press, 1990, 20: 110–118
SamuelssonB, RamwellPW, PaolettiR, FolcoG, GranstromE: Advances in prostaglandin, thromboxane and leukotriene research 21A: 331–414, 1991
GorsiniA, FolcoGG, FumagalliR, NicosiaS, NoeMA, OlivaD: (5Z)-carbacyclin discriminates between prostacyclin receptors coupled to adenylate cyclase in vascular smooth muscle and platelets. Br J Pharmacol 90: 255–261, 1987
MasudaA, MaisDE, OatisJE, HalushkaPV: Platelet and vascular thromboxane A2/prostaglandin H2 receptors—Evidence for different subclasses in the rat. Biochem Pharmacol 42: 537–544, 1991
GrossE, RuzickaT, MauchC, KriegT: Evidence for LTB4/12-HETE binding sites in a human epidermal cell line. Prostaglandins 36: 49–58, 1988
GrossE, RuzickaT, RestorffB, StolzW, KlotzK: Highaffinity binding and lack of growth-promoting activity of 12(S)-HETE in a human epidermal cell line. J Invest Dermatol 94: 446–451, 1990
SussR, ArenbergerP, GrossE, RuzickT: Regulation of 12(S)-HETE binding sites on human epidermal cells by interferon-γ. Exp Cell Res 191: 204–208, 1990
SmrckaAV, HelperJR, BrownKO, SternweisPC: Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq. Science 251: 804–807, 1991
Rouzer CA: Regulation and structure of human leukocyte 5-lipoxygenase. In: Crook ST, Wong A (eds) Lipoxygenases and their products. Academic Press, 1991, pp 51–65
Wong A: Regulation of 5-lipoxygenase activity in rat basophilic leukemia cells. In: Crook ST, Wong A (eds) Lipoxygenases and their products. Academic Press, 1991, pp 67–87
Kramer RM, Johansen B, Hession C, Pepinsky RB: Characterization of a secretable phospholipase A2 from human platelets. In: Samuelsson B, Dahlen S, Fritsch J, Hedqvist P (eds) Advances in prostaglandin, thromboxane and leukotriene research. Raven Press, 1990, 20: 79–86
HeinriksonRL, KruegerET, KeimPS: Amino acid sequence of phospholipase A2-α from venom of crotalus adamanteus, a new classification of phospholipases A2 based upon structural determinants. J Biol Chem 252: 4913–4921, 1977
Lapetina EG, Crouch MF: Relationship of inositol phospholipid metabolism to phospholipase A2. In: Samuelsson B, Wong PYK, Sun FF (eds) Advances in prostaglandin, thromboxane and leukotriene research. Raven Press, 1989, 19: 568–573
ClarkMA, OzgurLE, ConwayTM, DispotoJ, CrookST, BomalaskiJS: Cloning of a phospholipase A2-activating protein. Proc Natl Acad Sci USA 88: 5418–5422, 1991
PashJM, BaileyJM: Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. FASEB J 2: 2613–2618, 1988
Chang WC, Ning CC, Lin MT, Huang JD: Epidermal growth factor enhances a microsomal 12-lipoxygenase activity in A431 cells. In: Nigam S, Honn KV, Marnett LJ, Walden T (eds) Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Kluwer Academic Publishers, 1992, pp 463–466
Glasgow WC, Eling TE: Epidermal growth factor regulation of linoleic acid metabolism in syrian hamster embryo fibroblasts. In: Nigam S, Honn KV, Marnett LJ, Walden T (eds) Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Kluwer Academic Publishers, 1992, pp 467–470
Wong A, Hwang SM, Cook MN: The regulation of 5-lipoxygenase activity in rat basophilic leukemia cells. In: Samuelsson B, Dahlen S, Fritsch J, Hedqvist P (eds) Advances in prostaglandin, thromboxane and leukotriene research. Raven Press, 1990, 20: 28–34
FunkCD, FitzgeraldGA: Eicosanoid forming enzyme mRNA in human tissues. J Biol Chem 266: 12508–12513, 1991
MillerDK, GillardJW, VickersPJ, SadowskiS, LeveilleC, ManciniJA, CharlesonP, DixonRAF, Ford-HutchinsonAW, FortinR, GauthierJY, RodkeyJ, RosenR, RouzerC, SigalIS, StraderCD, EvansJF: Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343: 278–281, 1990
DixonRAF, DiehlRE, OpasE, RandsE, VickersPJ, EvansJF, GillardJW, MillerDK: Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282–284, 1990
ReidGK, KargmanS, VickersPJ, MancinJA, LeveilleC, EthierD, MillerDK, GillardJW, DixonRAF, EvansJF: Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. J Biol Chem 265: 19818–19823, 1990
AgarwallKC, ParksREJr: Foskolin: a potential anti-metastatic agent. Int J Cancer 32: 801–804, 1983
HonnKV: Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Expl Metastasis 1: 103–114, 1983
TanakaK, FukumotoS: Cancer blood-borne metastasis and platelets. Jpn J Cancer Chemother 11: 2453–2459, 1984
KarpatkinS, AmbrogioC, PearlsteinE: Lack of effect ofin vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT 26 colon carcinoma, Lewis lung carcinoma, or B16a amelanotic melanoma cells. Cancer Res 44: 3880–3883, 1984
GorelikE, BereWW, HerbermanRB: Role of NK cells in the metastatic effect of anticoagulant drugs. Int J Cancer 33: 87–94, 1984
JeneyA, LapisK, KopperL, PalK, TimarF, InstitorisL, GalambosG: Tumor progression and prostaglandins. In: MuszbekL (ed) Hemostasis and Cancer. CRC Press, Inc., Boca Raton, FL, 1987, pp 207–214
MahalingamM, UgenKE, KaoKJ, KleinPA: Functional role platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants. Cancer Res 48: 1460–1464, 1988
CostantiniV, FuschiottiP, AllegrucciA, NencilGG, FiorettiMC: Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analog on metastasis formation. Cancer Chemother Pharmacol 22: 289–293, 1988
NiitsuY, IshigakiS, KogawaK, MogiY, WatanabeN, KohgoY, UrushizakiI: Effect of combined administration of a prostacyclin analogue and adriamycin against the artificial metastasis of Meth A cell. Invasion Metastasis 8: 57–72, 1988
SavaG, PerissinL, ZorzetS, PicciniP, GiraldiT: Anti-metastatic action of the prostacyclin analog iloprost in the mouse. Clin Expl Metastasis 7: 671–678, 1989
KatoS, KobariM, MatsunoS, SatoT: Inhibitory effect of anti-platelet prostaglandin on liver metastasis of hamster pancreatic cancer. J Jpn Surg Society 90: 745–752, 1989
TzanakakisGN, AgarwallKC, VezeridisMP: Inhibition of hepatic metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude mouse by prostacyclin, forskolin, and ketoconazole. Cancer 65: 446–451, 1990
LapisK, TimarJ, PapayJ, PakuS, SzendeB, LadanyiA: Experimental metastasis inhibition by pretreatment of the host. Arch Geschwulstforsch 60: 97–102, 1990
ConstantiniV, GiampietriA, AllegrucciM, AgnelliG, NenciGG, FiorettiMC: Mechanisms of the antimetastatic activity of stable prostacyclin analogues: modulation of host immunocompetence. Adv Prostaglandin Thromboxane Leukotriene Res 21: 917–920, 1990
SchneiderMR, SchillingerE, SchirnerM, SkuballaW, SturzebeckerS, WittW: Effects of prostacyclin analogues inin vivo tumor models. Adv Prostaglandin Thromboxane Leukotriene Res 21: 901–908, 1990
GiraldiT, RapozziV, PerissinL, ZorzetS: Antimetastatic action of stable prostacyclin analogs in mice. Adv Prostaglandin Thromboxane Leukotriene Res 21: 913–916, 1990
SchirnerM, SchneiderMR: Cicaprost inhibits metastasis of animal tumors. Prostaglandins 42: 451–461, 1991
SchneiderMR, SchirnerM: Demonstration of antimetastatic effects of prostacyclin analoguesin vivo. In: NigamS, HonnKV, MarnettLJ, WaldenT (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Kluwer Academic Publishers, Boston, 1992, pp 657–662
HonnKV, MeyerJ: Thromboxane and prostacyclin: Positive and negative modulators of tumor growth. Biochem Biophys Res Commun 102: 1122–1129, 1981
HonnKV, SloaneBF: Prostacyclin, thromboxanes, and hematogenous metastasis. Adv Prostaglandin Thromboxane Leukotriene Res 12: 313–319, 1983
HonnKV, OnodaJM, MenterDG, TaylorJD, SloaneBF: Prostacyclin in the control of tumor metastasis. In: CohenMM (ed) Biologic Protection With Prostaglandins. CRC Press, Inc., Boca Raton, FL, 1985, pp 92–110
Honn KV, Onoda JM, Menter DG, Cavanaugh PG, Taylor JD, Crissman JD, Ryan RE, Sloane BF: Possible strategies for antimetastatic therapy. In: Welch DR, Bhuyan BK, Liotta L (eds) Cancer Metastasis: Experimental and Clinical Strategies. Alan R. Liss, Inc., 1986, pp 217–246
MenterDG, SteinertBW, SloaneBF, TaylorJD, HonnKV: A newin vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis. Cancer Res 47: 2425–2432, 1987
VergoteIB, vanDamPA, LaekemanGM, KeersemaeckersGH, UyttenbroeckFL, HermanAG: Prostacyclin/thromboxane ratio in human breast cancer. Tumour Biol 12: 261–266, 1991
StolmanGJ: Plasma thromboxane A2 and prostacyclin concentrations in squamous cell carcinoma of the head and neck. J Surg Oncol 38: 33–37, 1988
Aitokallio-TallbergAM, JungJK, KimSJ, ViinikkaLU, YlikorkalaRO: Urinary excretion of degradation products of prostacyclin and thromboxanes is increased in patients with gestational choriocarcinoma. Cancer Res 51: 4146–4148, 1991
MehtaP, LawsonD, WardMB, Lee-AmbroseL, KimuraA: Effects on thromoxane A2 inhibition on osteogenic sarcoma cell-induced platelet aggregation. Cancer Res 46: 5061–5063, 1986
RadomskyMW, JenkinsDC, HolmesL, MoncadaS: Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 51: 6073–6078, 1991
TohgoA, TanakaNG, OsadaY: Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium. Invasion Metastasis 10: 1–17, 1990
MenterDG, OnodaJM, TaylorJD, HonnKV: Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res 44: 450–456, 1984
MenterDG, OnodaJM, MoilanenD, SloaneBF, TaylorJD, HonnKV: Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. JNCI 78: 961–969, 1987
HonnKV, DunnJR: Nafazatrom (Bay g6575) inhibition of tumor cell lipoxygenase activity and cellular proliferation. FEBS Lett 139: 65–68, 1982
OnodaJM, SloaneBF, HonnKV: Antithrombogenic effects of calcium channel blockers: Synergism with prostacyclin and thromboxane synthase inhibitors. Thromb Res 34: 367–378, 1984
LambNJC, FernandezA, FeramiscoJR, WelchWJ: Modulation of vimentin containing intermediate filament distribution and phosphorylation in living fibroblasts by the cAMP-dependent protein kinase. J Cell Biol 108: 2409–2422, 1989
vanWilligenG, AkkermanJ-WN: Protein kinase C and cyclic AMP regulated reversible exposure of binding sites for fibrinogen on the glycoprotein IIB-IIIA complex of human platelets. Biochem J 273: 115–120, 1991
LiuB, TimarJ, HowlettJ, DiglioCA, HonnKV: Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regulation 2: 1045–1055, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chen, Y.Q., Liu, B., Tang, D.G. et al. Fatty acid modulation of tumor cell-platelet-vessel wall interaction. Cancer Metast Rev 11, 389–409 (1992). https://doi.org/10.1007/BF01307189
Issue Date:
DOI: https://doi.org/10.1007/BF01307189